| Title |
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic
|
|---|---|
| Published in |
Annals of Hematology, December 2016
|
| DOI | 10.1007/s00277-016-2888-3 |
| Pubmed ID | |
| Authors |
Ariana Berenson, Suzie Vardanyan, Michael David, James Wang, Nika Manik Harutyunyan, Jillian Gottlieb, Ran Halleluyan, Tanya M. Spektor, Kyle A. Udd, Shahrooz Eshaghian, Youram Nassir, Benjamin Eades, Regina Swift, James R. Berenson |
| Abstract |
Despite recent advances made in its treatment, multiple myeloma (MM) remains an incurable B cell malignancy. Thus, the objective for treating these patients is to prolong overall survival (OS) and preserve patients' quality of life. We have analyzed data from 264 consecutive MM patients who had their initial visit between July 1, 2004 and December 1, 2014 and have received treatment in a single clinic specializing in MM. We determined their progression-free survival (PFS, OS, and 5-year OS). The PFS for frontline (n = 165 treatments), salvage (n = 980), and all treatments (n = 1145) were 13.9, 4.6, and 5.5 months, respectively. The median OS of all patients was 98 months with a 5-year survival of 74%. The results of this study show a marked improvement in OS for unselected MM patients compared with historical data. There were no significant differences in OS between patients with different International Staging System (ISS) stages. Younger patients (<65 years old) showed a longer OS. The results of this study should help physicians predict outcomes for MM patients and be encouraging for patients with this B cell malignancy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 29% |
| Researcher | 4 | 24% |
| Student > Postgraduate | 3 | 18% |
| Student > Bachelor | 1 | 6% |
| Unknown | 4 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 53% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 18% |
| Arts and Humanities | 1 | 6% |
| Immunology and Microbiology | 1 | 6% |
| Computer Science | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 2 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2018.
All research outputs
#3,144,885
of 22,957,478 outputs
Outputs from Annals of Hematology
#113
of 2,197 outputs
Outputs of similar age
#64,295
of 416,245 outputs
Outputs of similar age from Annals of Hematology
#2
of 19 outputs
Altmetric has tracked 22,957,478 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,197 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 416,245 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.